The global veterinary infectious diseases therapeutics market is expected to grow at a CAGR of 4.5% during the forecast period, from 2021 to 2030. The growth of this market is attributed to the increasing prevalence of zoonotic diseases and the rising demand for animal-based protein in developing countries. The increasing number of emerging pathogens and antibiotic resistance are also driving the growth of this market.
Antibiotics accounted for a major share in the global veterinary infectious diseases therapeutics market in 2017, followed by antiviral, antifungal, amebicides, and anthelmintics. Antibiotics are used as an effective treatment against bacterial infections caused by bacteria such as Salmonella or E coli that can be transmitted from animals to humans through food or water contamination. Antiviral drugs are used for treating viral infections such as influenza virus that can cause respiratory problems in humans and animals alike. Antifungal drugs are used for treating fungal infections caused by fungi such as Candida albicans which can cause skin rashes or yeast infection in humans and animals alike. Amebicides are used for treating amoebic infections caused by protozoa like Entamoeba histolytica which can cause dysentery or liver abscesses in humans and animals alike while anthelmintics are used for treating worm infestations caused by worms like Ascaris lumbricoides which can cause intestinal obstruction or enteritis in both human beings and animals alike.
- The increasing demand for animal-based protein in developing countries is also expected to fuel the growth of this market over the forecast period.
- The increasing number of pet owners in developed countries is also expected to drive this market's growth over the forecast period as they are more likely than others to spend on their pets' health care needs and treatments such as vaccines and antibiotics which are used for treating infections caused by bacteria or viruses that can be transmitted from animals to humans or vice versa.
Industry Growth Insights published a new data on “Veterinary Infectious Diseases Therapeutics Market”. The research report is titled “Veterinary Infectious Diseases Therapeutics Market research by Types (Antibiotics, Antiviral, Antifungal, Amebicides, Anthelmintics), By Applications (Swine, Chicken, Dog, Cat, Cow, Horse, Other), By Players/Companies Elanco Animal Health, Novartis Animal Health, Merck, Pfizer Animal Health, Sanofi, Boehringer Ingelheim Vetmedica, Dechra Animal Health, Ceva Sante Animale, Elanco Animal Health, Virbac”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Veterinary Infectious Diseases Therapeutics Market Research Report
By Type
Antibiotics, Antiviral, Antifungal, Amebicides, Anthelmintics
By Application
Swine, Chicken, Dog, Cat, Cow, Horse, Other
By Companies
Elanco Animal Health, Novartis Animal Health, Merck, Pfizer Animal Health, Sanofi, Boehringer Ingelheim Vetmedica, Dechra Animal Health, Ceva Sante Animale, Elanco Animal Health, Virbac
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
247
Number of Tables & Figures
173
Customization Available
Yes, the report can be customized as per your need.
Global Veterinary Infectious Diseases Therapeutics Market Report Segments:
The global Veterinary Infectious Diseases Therapeutics market is segmented on the basis of:
Types
Antibiotics, Antiviral, Antifungal, Amebicides, Anthelmintics
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Swine, Chicken, Dog, Cat, Cow, Horse, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Elanco Animal Health
- Novartis Animal Health
- Merck
- Pfizer Animal Health
- Sanofi
- Boehringer Ingelheim Vetmedica
- Dechra Animal Health
- Ceva Sante Animale
- Elanco Animal Health
- Virbac
Highlights of The Veterinary Infectious Diseases Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Antibiotics
- Antiviral
- Antifungal
- Amebicides
- Anthelmintics
- By Application:
- Swine
- Chicken
- Dog
- Cat
- Cow
- Horse
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Veterinary Infectious Diseases Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Veterinary Infectious Diseases Therapeutics (VIDT) is a global biopharmaceutical company focused on the development and commercialization of novel therapeutics to address infectious diseases. The company's product candidates include vaccines and therapeutic antibodies against viruses, bacteria, fungi, and other pathogens. VIDT also develops companion diagnostics for the early detection of infections in animals.
Some of the major companies in the veterinary infectious diseases therapeutics market are Elanco Animal Health, Novartis Animal Health, Merck, Pfizer Animal Health, Sanofi, Boehringer Ingelheim Vetmedica, Dechra Animal Health, Ceva Sante Animale, Elanco Animal Health, Virbac.
The veterinary infectious diseases therapeutics market is expected to grow at a compound annual growth rate of 4.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Veterinary Infectious Diseases Therapeutics Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Veterinary Infectious Diseases Therapeutics Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Veterinary Infectious Diseases Therapeutics Market - Supply Chain
4.5. Global Veterinary Infectious Diseases Therapeutics Market Forecast
4.5.1. Veterinary Infectious Diseases Therapeutics Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Veterinary Infectious Diseases Therapeutics Market Size (000 Units) and Y-o-Y Growth
4.5.3. Veterinary Infectious Diseases Therapeutics Market Absolute $ Opportunity
5. Global Veterinary Infectious Diseases Therapeutics Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Veterinary Infectious Diseases Therapeutics Market Size and Volume Forecast by Type
5.3.1. Antibiotics
5.3.2. Antiviral
5.3.3. Antifungal
5.3.4. Amebicides
5.3.5. Anthelmintics
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Veterinary Infectious Diseases Therapeutics Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Veterinary Infectious Diseases Therapeutics Market Size and Volume Forecast by Application
6.3.1. Swine
6.3.2. Chicken
6.3.3. Dog
6.3.4. Cat
6.3.5. Cow
6.3.6. Horse
6.3.7. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Veterinary Infectious Diseases Therapeutics Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Veterinary Infectious Diseases Therapeutics Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Veterinary Infectious Diseases Therapeutics Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Veterinary Infectious Diseases Therapeutics Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Veterinary Infectious Diseases Therapeutics Demand Share Forecast, 2019-2026
9. North America Veterinary Infectious Diseases Therapeutics Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Veterinary Infectious Diseases Therapeutics Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Veterinary Infectious Diseases Therapeutics Market Size and Volume Forecast by Application
9.4.1. Swine
9.4.2. Chicken
9.4.3. Dog
9.4.4. Cat
9.4.5. Cow
9.4.6. Horse
9.4.7. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Veterinary Infectious Diseases Therapeutics Market Size and Volume Forecast by Type
9.7.1. Antibiotics
9.7.2. Antiviral
9.7.3. Antifungal
9.7.4. Amebicides
9.7.5. Anthelmintics
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Veterinary Infectious Diseases Therapeutics Demand Share Forecast, 2019-2026
10. Latin America Veterinary Infectious Diseases Therapeutics Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Veterinary Infectious Diseases Therapeutics Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Veterinary Infectious Diseases Therapeutics Market Size and Volume Forecast by Application
10.4.1. Swine
10.4.2. Chicken
10.4.3. Dog
10.4.4. Cat
10.4.5. Cow
10.4.6. Horse
10.4.7. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Veterinary Infectious Diseases Therapeutics Market Size and Volume Forecast by Type
10.7.1. Antibiotics
10.7.2. Antiviral
10.7.3. Antifungal
10.7.4. Amebicides
10.7.5. Anthelmintics
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Veterinary Infectious Diseases Therapeutics Demand Share Forecast, 2019-2026
11. Europe Veterinary Infectious Diseases Therapeutics Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Veterinary Infectious Diseases Therapeutics Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Veterinary Infectious Diseases Therapeutics Market Size and Volume Forecast by Application
11.4.1. Swine
11.4.2. Chicken
11.4.3. Dog
11.4.4. Cat
11.4.5. Cow
11.4.6. Horse
11.4.7. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Veterinary Infectious Diseases Therpeutics Market Size and Volume Forecast by Type
11.7.1. Antibiotics
11.7.2. Antiviral
11.7.3. Antifungal
11.7.4. Amebicides
11.7.5. Anthelmintics
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Veterinary Infectious Diseases Therapeutics Demand Share, 2019-2026
12. Asia Pacific Veterinary Infectious Diseases Therapeutics Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Veterinary Infectious Diseases Therapeutics Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Veterinary Infectious Diseases Therapeutics Market Size and Volume Forecast by Application
12.4.1. Swine
12.4.2. Chicken
12.4.3. Dog
12.4.4. Cat
12.4.5. Cow
12.4.6. Horse
12.4.7. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Veterinary Infectious Diseases Therapeutics Market Size and Volume Forecast by Type
12.7.1. Antibiotics
12.7.2. Antiviral
12.7.3. Antifungal
12.7.4. Amebicides
12.7.5. Anthelmintics
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Veterinary Infectious Diseases Therapeutics Demand Share, 2019-2026
13. Middle East & Africa Veterinary Infectious Diseases Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Veterinary Infectious Diseases Therapeutics Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Veterinary Infectious Diseases Therapeutics Market Size and Volume Forecast by Application
13.4.1. Swine
13.4.2. Chicken
13.4.3. Dog
13.4.4. Cat
13.4.5. Cow
13.4.6. Horse
13.4.7. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Veterinary Infectious Diseases Therapeutics Market Size and Volume Forecast by Type
13.7.1. Antibiotics
13.7.2. Antiviral
13.7.3. Antifungal
13.7.4. Amebicides
13.7.5. Anthelmintics
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Veterinary Infectious Diseases Therapeutics Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Veterinary Infectious Diseases Therapeutics Market: Market Share Analysis
14.2. Veterinary Infectious Diseases Therapeutics Distributors and Customers
14.3. Veterinary Infectious Diseases Therapeutics Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Elanco Animal Health
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Novartis Animal Health
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Merck
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Pfizer Animal Health
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Sanofi
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Boehringer Ingelheim Vetmedica
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Dechra Animal Health
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Ceva Sante Animale
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Elanco Animal Health
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Virbac
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3.
